Gilles DULUC
Directeur de la Recherche Clinique et de l'Innovation

Jeanne PATARD
Directrice adjointe de la Recherche Clinique et de l'Innovation

Département Promotion Interne

Anne GIMBERT
Responsable
Tél 05.57.82.04.34
anne.gimbert@chu-bordeaux.fr

Talence, le 13/05/2025

Object : Interventional Clinical Trial's results posting to the European Clinical Trial register (EudraCT) of the European Medicines Agency (EMA).
In accordance of Directive 2001/20/CE
Study Title : MISOBOLD : Prostate cancer hypoxia using BOLD MRI and 18F-FMISO PET imaging
EudraCT Nbr : 2015-000377-12
Sponsor Nbr : CHUBX2014/26 / **ANSM Nbr** : 170339A-13
Transitioned study to the Regulation (EU) 536/2014 : no
Status of the study : Prematuraly ended study

The study has been prematuraly ended because of a staff turnover through the research staff. As a result the end of the regulatory authorization has been reached. No patient has been recruited in the study and the steering committee decided to close the study.

For the Head of the University Hospital of Bordeaux
and by delegation,
The Director of the Clinical research and Innovation

Gilles DULUC
par délégation Jeanne Patard, directrice adjointe